I have doubts on IMU's SP changing dramatically as I don't see...

I have doubts on IMU's SP changing dramatically as I don't see any near term catalysts. There is this perception that some how big pharma will take over IMU, but in reality, IMU aren't even leading in the oncolytic virus space. There are numerous other companies in this field and some are even ahead of IMU. Have a look at the current competitors of IMU https://www.nature.com/articles/s41392-023-01407-6#Tab1. There are several drugs in phase 1 and 2, indicating that all of these virotherapies have demonstrated some efficacy in killing cancer cell lines and reducing tumor burden in xenograft models. So IMU's CF33 does not seem all that special.

In fact, there are a few clinical trial in progress and clinical trials completed presentations at the SITC on oncolytic therapies that are different to IMU but addressing the same market of solid tumors. For instance, there are two presentations on an oncolytic therapy called RP1, a drug developed by the same researcher that discovered the only oncolytic therapy to be FDA approved, T-Vec. Thinking that big pharama will make a bid or license IMU's platform over other available options might be a bit delusional.

The current cash on hand only covers the clinical trials in progress. What about the clinical trials after phase 1? IMU are likely to raise more money in the future and Hopper is going to get a sweet bonus for raising cash again. The remuneration highlights an eye watering $3.9 million in cash payment to the key management personals and that is not including non-cash bonuses. Including non-cash bonuses the total key management compensation is $7.36 million which equates to 2.5% of current market cap. Pay has increased but the share price as decreased.